Risk of Serious Infection Associated with Agents that Target T-Cell Activation and Interleukin-17 and Interleukin-23 Cytokines

被引：9
作者：
Shoor, Stanford [1 ]
机构：
[1] Stanford Univ, 1000 Welch Rd Suite 203, Palo Alto, CA 94304 USA
来源：
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA | 2020年 / 34卷 / 02期
关键词：
Serious infection; Co-stimulatory molecule inhibitors; IL-17 and IL-23 inhibitors; MODIFYING ANTIRHEUMATIC DRUGS; NECROSIS-FACTOR INHIBITORS; SEVERE PLAQUE PSORIASIS; LONG-TERM EFFICACY; RHEUMATOID-ARTHRITIS; PHASE-III; FUSION PROTEIN; MODERATE; SAFETY; BELATACEPT;
D O I：
10.1016/j.idc.2020.02.001
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Co-stimulatory T-cell inhibitors are used in the treatment of rheumatoid arthritis and to prevent rejection of renal transplants. Inhibitors of the interleukin (IL)-17 cytokine are indicated for psoriasis, psoriatic arthritis and ankylosing spondylitis and anti- IL-23 drugs for psoriasis. Serious infections occur in 4.2% to 25.0% of co-stimulatory inhibitors and 1.0% to 2.0% with IL-17 or IL-23 inhibitors. Underlying disease, steroid dose greater than 7.5 to 10.0 mg, and comorbidities influence risk in individual patients. Opportunistic infections or reactivation of tuberculosis are rare.
引用
收藏
页码：179 / +
页数：12
相关论文
共 81 条
  • [41] Mori S, 2018, PLOS ONE, V12
  • [42] Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study
    Mrowietz, Ulrich
    Bachelez, Herve
    Burden, A. David
    Rissler, Michael
    Sieder, Christian
    Orsenigo, Roberto
    Chaouche-Teyara, Kamel
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 80 (05) : 1344 - 1352
  • [43] Nathalie- Balandraud N, 2017, PLOS ONE, V12, P1
  • [44] Safety and efficacy of guselkumab in Japanese patients with moderate-to-severe plaque psoriasis: a randomized, placebo-controlled, ascending-dose study
    Nemoto, O.
    Hirose, K.
    Shibata, S.
    Li, K.
    Kubo, H.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (03) : 689 - 696
  • [45] Efficacy and Safety of Belatacept Treatment in Renal Allograft Recipients at High Cardiovascular Risk-A Single Center Experience
    Neuwirt, Hannes
    Leitner-Lechner, Irmgard
    Kerschbaum, Julia
    Ertl, Michael
    Poeggsteiner, Florian
    Poelt, Nicolas
    Maetzler, Julius
    Sprenger-Maehr, Hannelore
    Rudnicki, Michael
    Schratzberger, Peter
    Eder, Iris E.
    Mayer, Gert
    [J]. JOURNAL OF CLINICAL MEDICINE, 2019, 8 (08)
  • [46] Nogueira M, 2019, DRUGS CONTEXT, V8
  • [47] Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J)
    Okubo, Y.
    Mabuchi, T.
    Iwatsuki, K.
    Elmaraghy, H.
    Torisu-Itakura, H.
    Morisaki, Y.
    Nakajo, K.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (02) : 325 - 332
  • [48] Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases
    Olesen, Caroline Meyer
    Coskun, Mehmet
    Peyrin-Biroulet, Laurent
    Nielsen, Ole Haagen
    [J]. PHARMACOLOGY & THERAPEUTICS, 2016, 159 : 110 - 119
  • [49] Safety of Abatacept in Rheumatoid Arthritis With Serologic Evidence of Past or Present Hepatitis B Virus Infection
    Padovan, Melissa
    Filippini, Matteo
    Tincani, Angela
    Lanciano, Elisabetta
    Bruschi, Eleonora
    Epis, Oscar
    Garau, Pietro
    Mathieu, Alessandro
    Celletti, Eleonora
    Giani, Leopoldo
    Tomietto, Paola
    Atzeni, Fabiola
    Puttini, Piercarlo Sarzi
    Zuliani, Francesca
    De Vita, Salvatore
    Trotta, Francesco
    Grilli, Anastasio
    Puoti, Massimo
    Govoni, Marcello
    [J]. ARTHRITIS CARE & RESEARCH, 2016, 68 (06) : 738 - 743
  • [50] A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis
    Papp, K. A.
    Reich, K.
    Paul, C.
    Blauvelt, A.
    Baran, W.
    Bolduc, C.
    Toth, D.
    Langley, R. G.
    Cather, J.
    Gottlieb, A. B.
    Thaci, D.
    Krueger, J. G.
    Russell, C. B.
    Milmont, C. E.
    Li, J.
    Klekotka, P. A.
    Kricorian, G.
    Nirula, A.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2016, 175 (02) : 273 - 286
123456789